Takeda Partners with Crescendo Biologics for Humabody®-based Oncology Therapeutics
By Natasha Berry
Pharma Deals Review: Vol 2016 Issue 11 (Table of Contents)
Published: 1 Nov-2016
DOI: 10.3833/pdr.v2016.i11.2204 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In the midst of a significant overhaul of its R&D operations, Takeda Pharmaceutical has partnered with UK-based Crescendo Biologics for the discovery, development and commercialisation of Humabody®-based therapeutics for undisclosed cancer indications in a deal potentially worth up to US$790 M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS